Tag: non hodgkin lymphoma nhl market demand

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Non Hodgkin Lymphoma (NHL) Market CAGR Outlook And Future Development

The non-Hodgkin lymphoma (NHL) market size has experienced significant expansion in recent years. It is forecast to increase from $10.86 billion in 2025 to $11.73 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.0%. The expansion observed during prior periods can be attributed to several factors, including the rising global occurrence of NHL, improvements in chemotherapy protocols, increased spending on healthcare, enhanced public knowledge of lymphatic cancers, and the development of oncology hospital facilities.

The non hodgkin lymphoma (nhl) market size is anticipated to experience substantial expansion in the coming years. It is projected to grow to $16.44 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This expansion during the forecast period is driven by the expanding pipeline of targeted therapies, increasing approvals of biologics, rising adoption of personalized medicine, broadened access in emerging markets, and an increase in stem cell transplant procedures. Key trends observed over the forecast period encompass the increasing embrace of immunotherapy and targeted therapy, more frequent application of combination treatment regimens, an enhanced emphasis on early and precise diagnosis, the broadening of personalized treatment protocols, and a move towards outpatient and home-based care models.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=15221451&type=smp&name=Non%20Hodgkin%20Lymphoma%20%28NHL%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Non Hodgkin Lymphoma (NHL) Market Development Factors: What’s Supporting Demand?

The significant prevalence of non-Hodgkin lymphoma is expected to propel the growth of the non-Hodgkin lymphoma market in the future. This condition is a cancer that develops within the lymphatic system, which forms part of the body’s immune system. The prevalence of non-Hodgkin lymphoma specifically indicates the number of individuals within a population who are currently diagnosed with or living with the condition at a given point in time. Non-Hodgkin lymphoma treatment aims to improve patient outcomes for those already diagnosed by targeting and managing the cancerous cells. For example, as reported in January 2023 by the American Cancer Society, a US-based cancer health organization, non-Hodgkin lymphoma constitutes 4% of all cancers. The organization projects that in 2023, it will impact approximately 80,550 Americans, including 44,880 males and 35,670 females. Furthermore, it is estimated that 20,180 people will die in 2023 as a result of non-Hodgkin lymphoma. Consequently, the high prevalence of non-Hodgkin lymphoma is a key factor driving the non-Hodgkin lymphoma market.

Non Hodgkin Lymphoma (NHL) Market Segment Analysis And Revenue Potential

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Non Hodgkin Lymphoma (NHL) Market Transformation Trends: What Innovations Are Driving Change?

Leading companies in the non-Hodgkin lymphoma market are increasingly concentrating on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to secure a competitive advantage. Epcoritamab-bysp (EPKINLY) is a subcutaneous immunotherapy under investigation, designed to target CD20-expressing B-cell malignancies, demonstrating encouraging outcomes in clinical trials, particularly for relapsed or refractory B-cell non-Hodgkin lymphoma. As an illustration, in November 2023, AbbVie Inc., a US-based pharmaceutical company, was granted breakthrough therapy designation (BTD) by the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This approval targeted the treatment of adult patients diagnosed with relapsed or refractory (R/R) follicular lymphoma (FL) following two or more prior therapies. Concurrently, the European Medicines Agency (EMA) confirmed a Type II application for epcoritamab (TEPKINLY) for the identical indication. These recent updates draw support from previously published results from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial examined the safety and initial efficacy of subcutaneous epcoritamab across 128 adult patients afflicted with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), which included FL.

Non Hodgkin Lymphoma (NHL) Market Key Players Shaping Industry Direction

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

View The Full Non Hodgkin Lymphoma (NHL) Market Report:

https://thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-NHL-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Non Hodgkin Lymphoma (NHL) Market Geographic Distribution And Regional Opportunities

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Non Hodgkin Lymphoma (NHL) Market Growth Potential: How Will Market Size Change Through 2030?

The non-Hodgkin lymphoma (NHL) market has experienced substantial expansion over recent years. From $10.86 billion in 2025, it is expected to reach $11.73 billion by 2026, progressing at a compound annual growth rate (CAGR) of 8.0%. This historical growth is driven by a global increase in NHL incidence rates, improved chemotherapy treatments, higher healthcare spending, enhanced awareness of lymphatic cancers, and the expansion of oncology hospital facilities.

The non-Hodgkin lymphoma (NHL) market is anticipated to experience substantial expansion in the coming years, with projections indicating it will reach $16.44 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.8%. This forecasted growth is driven by several factors, including an expanding pipeline of targeted therapies, an uptick in approvals for biologics, a greater embrace of personalized medicine, improved access in emerging markets, and an increase in stem cell transplant procedures. Key trends shaping this period encompass the rising adoption of immunotherapy and targeted therapies, a greater utilization of combination treatment regimens, a heightened emphasis on early and precise diagnosis, the broadening of personalized treatment approaches, and a transition toward outpatient and home-based care delivery models.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Non Hodgkin Lymphoma (NHL) Market Growth Drivers And Industry Catalysts

Growing cases of non-Hodgkin lymphoma are set to drive expansion in the market for this condition moving forward. This type of cancer originates in the lymphatic system, a crucial component of the immune system. Its prevalence indicates how many individuals within a given population are currently diagnosed or living with this disease at a particular point in time. Treatments for non-Hodgkin lymphoma aim to improve outcomes for affected patients by targeting and controlling cancerous cells. As an example, data from the American Cancer Society, a cancer-focused health organization based in the US, revealed in January 2023 that non-Hodgkin lymphoma constitutes 4% of all cancers, with an estimated 80,550 Americans expected to be impacted in 2023—44,880 males and 35,670 females. The organization also projects that approximately 20,180 individuals will succumb to the disease in 2023. Consequently, the widespread occurrence of non-Hodgkin lymphoma is fueling growth in this specific market.

Non Hodgkin Lymphoma (NHL) Market Categorization By Product Type And Application

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Non Hodgkin Lymphoma (NHL) Market Trends Influencing Long-Term Demand

Major pharmaceutical players in the non-Hodgkin lymphoma sector are intensifying their efforts to develop advanced immunotherapies, including Epcoritamab-bysp (EPKINLY), as a strategy to secure market dominance. This investigational subcutaneous treatment is specifically engineered to target CD20-positive B-cell malignancies, and it has demonstrated notable efficacy in clinical studies, particularly for patients dealing with relapsed or refractory B-cell non-Hodgkin lymphoma. A key development occurred in November 2023, when AbbVie Inc., a U.S.-based pharmaceutical firm, secured a breakthrough therapy designation from the U.S. Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This regulatory nod applies to adults suffering from relapsed or refractory follicular lymphoma who have undergone at least two prior treatment regimens. Furthermore, the European Medicines Agency has accepted a Type II application submission for epcoritamab (TEPKINLY) targeting the same patient population. These milestones are backed by findings from the Phase 1/2 EPCORE NHL-1 trial, which examined the safety and early effectiveness of subcutaneous epcoritamab in a cohort of 128 adult patients with relapsed, progressive, or refractory CD20-positive mature B-cell non-Hodgkin lymphoma, including follicular lymphoma.

Non Hodgkin Lymphoma (NHL) Market Company Landscape And Strategic Competition

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Access The Complete Non Hodgkin Lymphoma (NHL) Market Report:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Non Hodgkin Lymphoma (NHL) Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Non Hodgkin Lymphoma (NHL) Market From 2026 To 2030?

The non-Hodgkin lymphoma (NHL) market has witnessed substantial expansion in recent years. It is anticipated to increase from $10.86 billion in 2025 to $11.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historical growth can be linked to factors like the rising global occurrence of NHL, advancements in chemotherapy protocols, increased healthcare spending, heightened awareness of lymphatic cancers, and the growth of oncology hospital infrastructure.

The non-Hodgkin lymphoma (NHL) market is poised for significant expansion in the coming years. Its valuation is projected to reach $16.44 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.8%. This anticipated growth during the forecast period is primarily attributed to factors such as the expanding pipeline of targeted therapies, an increase in biologic approvals, the growing uptake of personalized medicine, broader market access in developing regions, and the rise in stem cell transplant procedures. Key trends shaping the market during this period include a greater embrace of immunotherapy and targeted therapies, more frequent application of combination treatment regimens, an enhanced emphasis on prompt and precise diagnosis, the development of personalized treatment protocols, and a move towards outpatient and at-home care models.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Market Drivers Are Helping Shape The Non Hodgkin Lymphoma (NHL) Market Expansion?

The non-Hodgkin lymphoma market is projected to expand due to the significant occurrence of non-Hodgkin lymphoma. This form of cancer originates in the lymphatic system, a component of the body’s immune defense. Non-Hodgkin lymphoma prevalence signifies the total count of individuals within a population presently diagnosed with or affected by the condition at a given moment. Treatments for non-Hodgkin lymphoma enhance the prospects for those already diagnosed by targeting and controlling cancer cells. For example, data from January 2023 by the American Cancer Society, a US-based cancer health organization, indicates that non-Hodgkin lymphoma constitutes 4% of all cancers. In 2023, approximately 80,550 Americans are expected to be affected, comprising 44,880 males and 35,670 females. The society also forecasts 20,180 fatalities in 2023 attributed to non-Hodgkin lymphoma. Consequently, the substantial prevalence of non-Hodgkin lymphoma acts as a key driver for the non-Hodgkin lymphoma market.

What Key Segment Areas Are Included In The Non Hodgkin Lymphoma (NHL) Market Assessment?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Which Trends Are Shaping The Non Hodgkin Lymphoma (NHL) Market Landscape?

Key companies operating in the non-Hodgkin lymphoma market are increasing their focus on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to gain a competitive advantage. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy designed to target CD20-expressing B-cell malignancies, showing promising results in clinical trials, particularly in relapsed or refractory B-cell non-Hodgkin lymphoma. For instance, in November 2023, AbbVie Inc., a US-based pharmaceutical company, received a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). The approval was granted for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more therapies. Additionally, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These updates were supported by previously announced results from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial evaluated the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), including FL.

Which Companies Form The Competitive Landscape Of The Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Access The Complete Non Hodgkin Lymphoma (NHL) Market Report:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Region Has The Strongest Presence In The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Non Hodgkin Lymphoma (NHL) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2026, By The Business Research Company

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Non Hodgkin Lymphoma (NHL) Market Between 2026 And 2030?

Significant growth has been observed in the non hodgkin lymphoma (nhl) market size over recent years. It is projected to expand from $10.86 billion in 2025 to $11.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historical growth can be attributed to factors such as the rising incidence of nhl globally, advances in chemotherapy regimens, increasing healthcare expenditure, growing awareness of lymphatic cancers, and the expansion of oncology hospital infrastructure.

The non hodgkin lymphoma (nhl) market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $16.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This growth over the forecast period is fueled by several factors, including the expanding pipeline of targeted therapies, an increase in biologics approvals, the growing embrace of personalized medicine, broader market access in developing regions, and the rise in stem cell transplant procedures. Key trends influencing this period encompass the increased uptake of immunotherapy and targeted therapy, a greater reliance on combination treatment regimens, an enhanced emphasis on early and precise diagnosis, the development of personalized treatment protocols, and a move towards outpatient and home-based care models.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Leading Drivers Are Supporting The Non Hodgkin Lymphoma (NHL) Market Expansion?

The non-Hodgkin lymphoma market is expected to grow significantly, driven by the high occurrence of the condition. This cancer originates within the lymphatic system, a vital part of the body’s immune defense. The prevalence of non-Hodgkin lymphoma specifically refers to the count of individuals in a given population who are currently diagnosed with or living with the disease at a particular time. Non-Hodgkin lymphoma treatments are essential for improving outcomes for diagnosed individuals by effectively targeting and managing the cancer cells. For instance, in January 2023, data from the American Cancer Society, a US-based cancer health organization, showed that non-Hodgkin lymphoma accounts for 4% of all cancers and is anticipated to affect approximately 80,550 Americans in 2023, comprising 44,880 males and 35,670 females. The organization further estimates that 20,180 people will die in 2023 due to non-Hodgkin lymphoma. Thus, the substantial prevalence of non-Hodgkin lymphoma is a major impetus for the non-Hodgkin lymphoma market.

What Are The Key Segment Divisions In The Non Hodgkin Lymphoma (NHL) Market Segment Structure?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What Emerging Trends Are Seen In The Non Hodgkin Lymphoma (NHL) Market?

Leading companies in the non-Hodgkin lymphoma market are increasingly focused on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to achieve a competitive advantage. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy designed to target CD20-expressing B-cell malignancies, demonstrating promising results in clinical trials, particularly for relapsed or refractory B-cell non-Hodgkin lymphoma. For instance, in November 2023, AbbVie Inc., a US-based pharmaceutical company, obtained a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This approval pertains to the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more prior therapies. Additionally, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These advancements are supported by previously announced results from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial assessed the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), including FL.

Which Organizations Are Engaged In The Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Get The Full Non Hodgkin Lymphoma (NHL) Market Report:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Region Is The Leading Market For The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Non Hodgkin Lymphoma (NHL) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2026, By The Business Research Company

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Non Hodgkin Lymphoma (NHL) Market At The End Of The 2026–2030 Forecast Period?

The non-Hodgkin lymphoma (NHL) market has experienced substantial growth in recent years. Its value is projected to increase from $10.86 billion in 2025 to $11.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The expansion observed in prior periods is attributable to several factors, including a global rise in NHL cases, advancements in chemotherapy treatments, increased healthcare spending, greater public understanding of lymphatic cancers, and the development of oncology hospital facilities.

The non-Hodgkin lymphoma (NHL) market size is anticipated to undergo significant expansion in the coming years, projected to reach $16.44 billion by 2030, with a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period is attributable to the expanding pipeline of targeted therapies, a rise in biologic approvals, increasing adoption of personalized medicine, broadening access in emerging markets, and an uptick in stem cell transplant procedures. Key trends expected in this period include the rising uptake of immunotherapy and targeted therapy, more widespread use of combination treatment regimens, an increased focus on early and accurate diagnosis, the expansion of personalized treatment protocols, and a shift towards outpatient and home-based care models.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Drivers Are Shaping The Future Growth Of The Non Hodgkin Lymphoma (NHL) Market?

The non-Hodgkin lymphoma market is expected to grow, primarily driven by the high prevalence of non-Hodgkin lymphoma. This cancer originates in the lymphatic system, which is an integral part of your immune system. The prevalence of non-Hodgkin lymphoma indicates the number of individuals in a population currently diagnosed with or living with the condition at a specific time. Treatments for non-Hodgkin lymphoma aid in improving outcomes for those already diagnosed by targeting and managing cancer cells. For instance, in January 2023, the American Cancer Society, a US-based cancer health organization, reported that non-Hodgkin lymphoma represents 4% of all cancers. Additionally, it is projected to affect around 80,550 Americans in 2023, consisting of 44,880 males and 35,670 females. The organization further estimates that 20,180 people will die in 2023 due to non-Hodgkin lymphoma. Therefore, the significant prevalence of non-Hodgkin lymphoma is a key factor driving the non-Hodgkin lymphoma market.

What Segment Types Make Up The Non Hodgkin Lymphoma (NHL) Market?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Which Market Trends Are Creating New Opportunities In The Non Hodgkin Lymphoma (NHL) Market?

Major companies within the non-Hodgkin lymphoma market are increasingly concentrating on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to achieve a competitive advantage. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy specifically designed to target CD20-expressing B-cell malignancies, demonstrating promising results in clinical trials, particularly in relapsed or refractory B-cell non-Hodgkin lymphoma. For example, in November 2023, AbbVie Inc., a US-based pharmaceutical company, secured a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This approval was granted for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more therapies. Additionally, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These recent updates are substantiated by previously announced outcomes from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial assessed the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients afflicted with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), including FL.

Who Are The Key Players Driving Competition In The Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Read the full non hodgkin lymphoma (nhl) market report here:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Geographic Regions Are Influencing Demand In The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Non Hodgkin Lymphoma (NHL) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2026, By The Business Research Company

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the non hodgkin lymphoma (nhl) market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Non Hodgkin Lymphoma (NHL) Market by the end of 2030?

The non hodgkin lymphoma (nhl) market size has experienced robust expansion in recent years. Forecasts indicate it will expand from $10.86 billion in 2025 to reach $11.73 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.0%. Historically, this growth has been driven by several factors, including a global increase in NHL incidence, advancements in chemotherapy protocols, rising healthcare spending, greater public awareness of lymphatic cancers, and the development of oncology hospital facilities.

The non hodgkin lymphoma (nhl) market is anticipated to experience substantial expansion over the next few years, projected to reach $16.44 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.8%. This growth during the forecast period is driven by factors such as the expanding pipeline of targeted therapies, increasing approvals of biologics, the rising adoption of personalized medicine, broadening access in emerging markets, and an increase in stem cell transplant procedures. Significant trends expected in this period include the growing embrace of immunotherapy and targeted therapy, a rise in the use of combination treatment regimens, an increased emphasis on early and accurate diagnosis, the expansion of personalized treatment protocols, and a shift towards outpatient and home-based care models.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Drivers Are Shaping Future Opportunities In The Non Hodgkin Lymphoma (NHL) Market?

The elevated occurrence of non-Hodgkin lymphoma is projected to stimulate the expansion of the non-Hodgkin lymphoma market. This particular cancer forms within the lymphatic system, which is an integral part of the body’s immune defenses. The prevalence of non-Hodgkin lymphoma specifically denotes the count of individuals within a population who are presently diagnosed with or living with this ailment at a particular juncture. Treatments for non-Hodgkin lymphoma are designed to enhance outcomes for diagnosed individuals by targeting and managing cancerous cells. As an illustration, in January 2023, the American Cancer Society, a US-based cancer health organization, reported that non-Hodgkin lymphoma constitutes 4% of all cancers, and in 2023, it is predicted to affect approximately 80,550 Americans, including 44,880 males and 35,670 females. Additionally, the society estimates that 20,180 people will die in 2023 due to non-Hodgkin lymphoma. Consequently, the significant prevalence of non-Hodgkin lymphoma serves as a key impetus for the non-Hodgkin lymphoma market.

Which Segment Groups Are Influencing The Non Hodgkin Lymphoma (NHL) Market?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What Industry Trends Are Transforming The Non Hodgkin Lymphoma (NHL) Market?

Leading companies within the non-Hodgkin lymphoma market are intensifying their efforts to launch innovative immunotherapies, specifically Epcoritamab-bysp (EPKINLY), aiming to secure a competitive advantage. Epcoritamab-bysp (EPKINLY) is an experimental subcutaneous immunotherapy developed to target CD20-expressing B-cell malignancies, demonstrating encouraging outcomes in clinical trials, especially for relapsed or refractory B-cell non-Hodgkin lymphoma. An example of this is AbbVie Inc., a US-based pharmaceutical company, which secured a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY) in November 2023. This designation was awarded for its use in treating adult patients diagnosed with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more therapies. Furthermore, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) concerning the identical indication. These developments draw support from earlier published findings of the Phase 1/2 EPCORE NHL-1 clinical trial. This trial assessed the safety and initial effectiveness of subcutaneous epcoritamab in 128 adult patients afflicted with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), encompassing FL.

Who Are The Major Companies Operating In The Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non Hodgkin Lymphoma (NHL) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2026, By The Business Research Company

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the non hodgkin lymphoma (nhl) market from 2025–2034 with trusted insights from The Business Research Company

How Is The Non Hodgkin Lymphoma (NHL) Market Size Expected To Expand Over 2029-2034?

The non hodgkin lymphoma (NHL) market size has experienced significant expansion over recent years. Projections indicate it will rise from $10.11 billion in 2024 to $10.86 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.5%. This historical growth can be attributed to several factors, including the rising incidence of NHL, progress in diagnostic methods, the development of chemotherapy and immunotherapy, ongoing clinical research and drug creation, and enhanced survival rates.

The non hodgkin lymphoma (NHL) market size is anticipated to experience robust expansion over the coming years. It is projected to reach ” $15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.4%. This projected growth during the forecast period is attributable to factors such as an expanding aging demographic, progress in targeted therapies, breakthroughs in immunotherapy, adoption of precision medicine strategies, and enhanced awareness leading to earlier detection. Key developments expected during this period involve the emergence of biosimilars, the incorporation of next-generation sequencing, the increasing use of car-t cell therapies, the introduction of new chemotherapy agents, and a focus on real-world evidence and outcomes research.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

Which Market Factors Are Fueling The Non Hodgkin Lymphoma (NHL) Industry Growth?

The significant prevalence of non-Hodgkin lymphoma is anticipated to boost the non-Hodgkin lymphoma market going forward. This condition is a cancer that develops in the lymphatic system, which forms part of the immune system. The prevalence of non-Hodgkin lymphoma indicates the number of individuals in a population who are currently diagnosed with or living with the condition at a specific time. Non-Hodgkin lymphoma treatment helps improve outcomes for individuals already diagnosed by targeting and managing the cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based cancer health organization, non-Hodgkin lymphoma makes up 4% of all cancers, and in 2023, it is projected to affect around 80,550 Americans, including 44,880 males and 35,670 females. It also estimates that 20,180 people will die in 2023 because of non-Hodgkin lymphoma. Furthermore, in May 2022, according to the Canadian Cancer Society, a Canada-based national cancer charity, non-Hodgkin lymphoma was expected to be diagnosed in 11,400 Canadians in the year 2022. It was also anticipated to claim the lives of 3,000 Canadians. Consequently, the high prevalence of non-Hodgkin lymphoma is driving the non-Hodgkin lymphoma market.

Which Categories Are Covered In The Non Hodgkin Lymphoma (NHL) Market Segmentation Analysis?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Which Market Trends Are Expected To Define The Future Of The Non Hodgkin Lymphoma (NHL) Market?

A notable trend gaining traction in the non-Hodgkin lymphoma market involves advancements in drug innovations. Companies operating in the non-Hodgkin market are concentrating on developing new products to sustain their market position. For instance, in December 2022, Genentech Inc., a US-based biotechnology company, obtained FDA approval for Lunsumio, a novel bispecific antibody intended for treating relapsed or refractory follicular lymphoma. This antibody represents a new class of fixed-duration cancer treatment immunotherapy, offering a readily available and off-the-shelf treatment option, which means patients do not need to wait to receive this immunotherapy. The FDA approval was based on favorable results from the Lunsumio Phase II GO29781 research conducted on individuals with extensively pretreated FL, particularly those at a high risk of illness progression or unresponsive to prior treatments.

Which Organizations Are At The Forefront Of The Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Geographic Areas Are Driving Strong Demand For The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2025, By The Business Research Company

Data Protection As A Service Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/data-protection-as-a-service-global-market-report

Cloud Security Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cloud-security-global-market-report

Application Security Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/application-security-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model